Spazmalgon ampoules 5ml N10
Condition: New product
1000 Items
Rating:
Be the first to write a review!
More info
Description
Solution for i / m injection Spasmalgon - antispasmodic agent of the combined composition, the combination of the components of which leads to a mutual strengthening of their pharmacological action. Metamizole sodium is an analgesic, antipyretic, pyrazolone derivative. It has a pronounced analgesic, antipyretic and weak anti-inflammatory effect, the mechanism of which is associated with inhibition of prostaglandin synthesis. Pitofenone hydrochloride is a myotropic antispasmodic, has a direct effect on the smooth muscles of the internal organs and causes its relaxation (papaverine-like effect). Fenpiverinium bromide, being m-anticholinergic, has an additional relaxing effect on smooth muscles.
Active ingredients
Metamizole sodium + Pitofenon + Fenpiverinium bromide
Release form
Ampoules
Composition
Metamizol sodium 500 mg 2.5 g, fenpiverinium bromide 20 mcg 100 mcg, pitofenone hydrochloride 2 mg 10 mg, water d / and.
Pharmacological effect
An antispasmodic is a combination drug with a pronounced spasmolytic and analgesic activity, also has an anti-inflammatory effect. Metamizole sodium has a pronounced analgesic and antipyretic effect in combination with the known anti-inflammatory ispasmolytic activity. Its effects are the result of a pronounced antinociceptive effect, influence on the hypothalamus and the formation of endogenous pyrogens, as well as inhibition of synthesis of prostaglandins as a result of inhibition of cyclooxygenase. biliary and urinary tract. Pitofenon hydrochloride has papaverine-like effect of pronounced myotropic spas asmolytic activity on smooth muscle.
Pharmacokinetics
An intramuscular spasmalgon is rapidly absorbed. With intramuscular and intramuscular administration, metamizole sodium creates systemic bioavailability up to 85%. Metamizole sodium undergoes intensive biotransformation in the body. Its main metabolites are 4-methylaminoantipirin, 4-formylaminoantipirin, 4-aminoantipyrin and 4-acetylaminoantipirin.About twenty additional metabolites have been identified, including sulfates and glucuronic acid conjugates. The main chemitmetabolite metamizole sodium is found in the cerebrospinal fluid and excreted in the mother's milk, and is associated with up to 60% of plasma proteins. It is eliminated mainly through the kidneys. Significant changes in the concentrations of metabolism of metamizole sodium metabolites have been established in patients with cirrhosis. The phenotype of acetylation does not change the pharmacokinetic behavior of metamizole sodium metabolites when it is used in high doses. Pitofenone hydrochloride and fenpiverinium bromide are slightly lipid soluble and completely ionized. Do not pass through the blood-brain and placental barriers. Metabolized in the liver. Excreted from the body mainly unchanged up to 90% in the urine and up to 10% in the diet. The half-life is about 10 hours.
Indications
Symptomatic treatment of pain in spasms of the smooth muscles of internal organs: - gastric or intestinal colic - renal colic in urolithiasis - spastic biliary dyskinesia - dysmenorrhea
Contraindications
- oppression of bone marrow hematopoiesis, - severe liver failure, - severe renal failure, - glucose-6-phosphate dehydrogenase deficiency, - tachyarrhythmia, - severe angina, - heart failure in the decompensation stage, - close-angle glaucoma, - prostatic hyperplasia, heart failure in the decompensation stage, - closed-angle glaucoma, - prostatic hyperplasia, heart failure in the decompensation stage, - closed angle glaucoma, - prostatic hypertrophy intestinal obstruction, - megacolon, - collapse, - pregnancy (especially I and III trimester), - lactation period (breastfeeding), - children up to 15 years old, - increased sensitivity NOSTA to the drug and other derivatives of pyrazolone.
Precautionary measures
With caution prescribed for renal or hepatic failure, bronchial asthma, "aspirin triad" (bronchial asthma, urticaria and acute rhinitis, provoked by taking acetylsalicylic acid or other NSAIDs), a tendency to arterial hypotension, hypersensitivity to NSAIDs.
Dosage and administration
Spasmalgon is administered intramuscularly. A single dose varies from 2 to 5 ml, depending on the type and severity of clinical symptoms.If there are indications, the injection can be repeated after 6-8 hours. But the duration of such an application should not exceed 2-3 days. In the absence of a therapeutic effect, the use of the drug should be discontinued, and with good or satisfactory effect, you can proceed to receive the oral dosage form. The maximum daily dose should not exceed 10 ml injection solution (respectively, 5 g of metamizole sodium). The duration of the treatment course is determined by the attending physician.
Side effects
- decrease in arterial pressure, tachycardia, cardiac rhythm disturbance - agranulocytosis, leukopenia, thrombocytopenia - dizziness - visual disturbances, disturbance of accommodation - dry mouth, constipation, exacerbation of gastritis and ulcerative stomach disease - urinary retention, proteinuria, oliguria, and Ipuriya. nephritis, red coloration, bronchospasmus, urticaria, urticaria, pruritus, Lyell's syndrome and Stevens-Johnson syndrome, toxic epidermal necrolysis, anaphylactic shock
Overdose
Symptoms: nausea, vomiting, gastralgia, oliguria, hypothermia, lowering blood pressure, tachycardia, shortness of breath, tinnitus, drowsiness, delusions, impaired consciousness, acute agranulocytosis, hemorrhagic syndrome. Treatment: gastric lavage, taking activated carbon, the use of water-salt solutions.
Interaction with other drugs
Contraindicated with the simultaneous use of radiopaque drugs, colloidal blood substitutes and penicillin. With simultaneous use of the drug with cyclosporine decreases the concentration of the latter in the blood. With simultaneous use of metamizole sodium, displacing oral hypoglycemic agents, indirect anticoagulants, GCS and indomethacin from the connection with the protein, increases their activity. With simultaneous use of phenylbutazone, barbiturates and other inducers of liver microsomal enzymes reduce the effectiveness of metamizole sodium. With simultaneous use with other non-narcotic analgesics, tricyclic antidepressants, oral hormonal contraceptives and allopurinol may increase toxicity. With simultaneous use of sedatives and anxiolytics (tranquilizers) increase the analgesic effect of spasmalgone.